Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease

British Journal of Ophthalmology

Volumn 94, Issue 3, 2010, Pages 381-383

  Shimura, Masahiko ^a   Yasuda, Kanako ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CREATININE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

AGED; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLYCEMIC CONTROL; HUMAN; KIDNEY DYSFUNCTION; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA FOVEA; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA EDEMA; THICKNESS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VASCULAR DISEASE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; ISCHEMIA; MACULA LUTEA; MALE; RETINAL VEIN OCCLUSION;

EID: 77949502148     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.160986     Document Type: Letter

References (6)

1. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin®) for macular edema secondary to retinal vein occlusiondtwelve-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
2. Kriechbaum K, Michels S, Prager F, et al. Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-22.
3. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
4. Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008;51:1574-80.
5. Pollack A, Leiba H, Oliver M. Progression of nonischemic central retinal vein occlusion. Ophthalmologica 1997;211:13-20.
6. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin®) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol Scand 2008;86:925-7.